Background: Aortic arch disease is a challenging clinical problem, especially in high-risk patients, in whom open repair can have morbidity and mortality rates of 30% to 40% and 2% to 20%, respectively. Aortic arch chimney (AAC) stents used during thoracic endovascular aortic repair (TEVAR) are a less invasive treatment strategy than open repair, but the current literature is inconclusive about the role of this technology. The focus of this analysis is on our experience with TEVAR and AAC stents.
of repair, including arch vessel debranching and extraanatomic bypass with simultaneous or staged thoracic endovascular aortic repair (TEVAR). [2] [3] [4] Outcomes of these techniques have mixed results, with morbidity and mortality rates of 30% to 40% and 10% to 15%, respectively. 5, 6 Although branched/fenestrated arch devices are less invasive, they are not widely available, are not designed to treat the full gamut of arch pathologic processes, and have ill-defined durability. 7 An alternative approach to proximal aortic disease management is use of aortic arch chimney (AAC) stents as adjuncts to TEVAR. [8] [9] [10] The concept of parallel chimney stents was first described as a "bailout" maneuver after inadvertent visceral vessel coverage during endovascular abdominal aortic repair. 11 Since the initial description, there has been rapid proliferation and application of chimney techniques in the management of paravisceral aortic disease. 9, [11] [12] [13] Not surprisingly, this technique is now being increasingly applied to more proximal aortic/arch disease treated during TEVAR. [14] [15] [16] [17] The allure of this approach is that it provides a nearly total endovascular solution and can be completed with readily available technologies using implantation techniques familiar to most operators performing TEVAR. In addition, this is a versatile technique that is applicable to elective and nonelective presentations for a variety of aortic diseases. However, AAC use during TEVAR is still an unproven strategy, and concerns about selection of patients, device choice, operative technique, durability, and long-term outcomes remain unresolved. Thus, we sought to review our experience with AAC techniques used during TEVAR.
METHODS
The study was approved by the University of Florida Institutional Review Board (#838-2014). The need for informed consent was waived because of the retrospective nature of the analysis.
Study cohort. A prospectively collected database was queried for TEVAR procedures performed with AAC stents between January 2002 and June 2015. AAC procedures were first attempted in our practice after 2009 because of our experience with visceral aortic chimney procedures. During this time, 968 patients underwent TEVAR at our institution, of whom 115 (12%) had Ishimaru 18 zone 0 and zone 1 deployments. Of this subset, 27 (23%) were deemed unfit for direct open repair or extra-anatomic arch debranching and underwent AAC stent placement. Planned or unplanned AAC procedures were included in the study, and patients who underwent simultaneous sternotomy, thoracotomy, or placement of a fenestrated/branched arch device (n ¼ 4) were excluded.
Patient demographics, comorbidities, and operative variables were extracted from the database and electronic medical record. The definitions and severity of comorbidities were described per the Society for Vascular Surgery guidelines. 19 All additional concurrent adjunctive procedures were described per reporting standards. 19 Postoperative computed tomography angiography (CTA) images were reviewed to verify chimney patency and to determine presence of endoleak. Reintervention was defined as any unplanned return to the operating room and was dichotomized into aortarelated and non-aorta-related indications.
Selection of patients and clinical practice. All patients were considered to be at prohibitively high risk for open surgical repair 20 because of the unique constellation of medical and anatomic factors that characterized each patient's presentation. Consensus opinion was obtained regarding risk for open repair in each case among members of the vascular surgery and thoracic/ cardiovascular surgery groups as previously reported. 21 For planned AAC procedures, patients and their families were thoroughly informed of the "off-label" nature of the procedure. Preoperatively, all patients underwent CTA with centerline, three-dimensional reconstruction (TeraRecon Inc, San Mateo, Calif) for planning. The treating surgeon was responsible for device selection and implantation technique. During the study period, our practice evolved from selective to routine, pre-emptive revascularization of the left subclavian artery (LSA) in cases of anticipated long-segment aortic coverage (>200 mm) in an effort to reduce spinal cord ischemia and stroke risk. 22, 23 Similarly, pre-emptive spinal drainage was increasingly used in extensive aortic coverage cases if the patient's clinical presentation allowed. Recommendation: The authors suggest that thoracic endovascular aortic repair with aortic arch chimney grafts can be completed with acceptable short-term morbidity and mortality, but reintervention and stroke remain significant concerns.
ARTICLE HIGHLIGHTS
Brachiocephalic chimney technique. All operations were performed under general anesthesia in hybrid operating rooms using fixed imaging, single-plane systems (Infinix VCi [Toshiba Medical Systems, Tokyo, Japan]; Artis zeego system [Siemens Medical Solutions USA, Inc, Malvern, Pa]). Depending on the planned configuration of the reconstruction, the brachiocephalic target vessels were exposed for retrograde delivery of branch stents, or a carotid-subclavian bypass was performed, through which a retrograde carotid stent graft was placed. Routinely, percutaneous access of the femoral arteries was used for TEVAR delivery as previously described. 24 Patients were systemically heparinized (80-100 units/kg) to achieve an activated clotting time $300 seconds before any wire manipulation of the aortic arch. A combination of digital subtraction angiography with intravascular ultrasound was used to minimize risk of unintended branch vessel compromise. The main thoracic endograft was delivered and deployed, with concomitant or subsequent deployment of the chimney stent, depending on the type of main aortic graft and the landing zone. For zone 0 or zone 1 implants, selective use of right atrial balloon occlusion or rapid ventricular pacing was employed. In cases of planned LSA coverage, the carotid-subclavian bypass was routinely completed before graft implantation. Typically, self-expanding stent grafts (eg, Gore Viabahn; W. L. Gore & Associates, Flagstaff, Ariz) were used for left common carotid artery (LCCA) chimneys because of their flexibility; however, these are often supported proximally with a balloon or selfexpandable stent graft (eg, iCAST [Atrium Maquet Getinge Group, Inc, Berlin, Germany] or Zilver 518 [Cook Medical, Inc, Bloomington, Ind]). Notably, because of the large diameters of the innominate artery that are frequently encountered, alternative self-expanding stent graft choices, such as iliac endograft limbs (eg, Zenith Flex TFLE/ZSLE; Cook Medical), were used (Figs 1 and 2 ; Supplementary Table I, online only).
Postoperative management. Spinal drain management and blood pressure goals were based on a previously published protocol. 23 Postoperative surveillance included CTA before discharge for patients undergoing nonelective procedures, followed by CTA at 1 month, 6 months, and annually thereafter. Unless it was contraindicated, patients were prescribed dual antiplatelet therapy (aspirin 81 mg/d and clopidogrel 75 mg/d) and a A, This image demonstrates a patient with a proximal descending thoracic aneurysm requiring a double chimney into the ascending aorta (zone 0). The carotid-subclavian bypass has been completed, and the left common carotid artery (LCCA) chimney, in this case a Gore Viabahn, is placed through the bypass graft. The innominate chimney stent, in this case an iliac limb device, has been delivered through the right axillary artery. The thoracic aortic endograft is also in place. Graft sizing is generally 30% greater than the outer-to-outer centerline aortic measurement at the anticipated landing zone (0%-10% in cases of dissection).
Overlap between the chimney and thoracic stent grafts is generally 3 cm or greater (especially if there is significant arch curvature). B, The device is partially deployed, with the proximal aspect still constrained while the chimney stents are deployed, which is demonstrated in (C). D, Concomitant ballooning of all three stents, with a compliant balloon in both the innominate and aortic stent grafts and a noncompliant balloon in the LCCA stent graft. This final ballooning often takes multiple surgeons working simultaneously to complete. With proximal deployment such as this, we often use a right atrial inflow occlusion balloon (not shown) that is delivered through right common femoral vein access to lower the blood pressure and to avoid shifting of the devices during ballooning. We advocate internal reinforcement of the chimney stent grafts with self-expanding stents. In this image, the left subclavian artery (LSA) has been embolized with a vascular plug.
statin (eg, simvastatin 20 mg/d) after the procedure. Clopidogrel was discontinued after 3 months, whereas aspirin and the statin agent were prescribed indefinitely. Need and timing of reinterventions were left to the discretion of the operating surgeon but were all adjudicated by multiple experienced cardiothoracic and vascular surgeons in the practice. Frequently, innominate chimney interventions were performed through right axillary artery access; left carotid chimney interventions were completed through left brachial artery access.
End points and definitions. The primary end points of the analysis were technical success and 30-day and 1-year mortality. Secondary end points included complications, reintervention, and endoleak. A significant stenosis of a chimney stent was defined as $50% decrease in luminal diameter on follow-up CTA. Technical success was defined by survival of the index operation with deployment of the AAC stent at the intended treatment zone and no evidence of type Ia or type III endoleak on the first follow-up CTA study. Mortality events were verified by query of the Social Security Death Masterfile.
Statistics. All statistical analyses were performed using Stata software (version 9.2; StataCorp LP, College Station, Tex). Categorical factors were summarized using frequencies and percentages, and continuous variables were described using means, medians, and standard deviations. Categorical variables and continuous measures were compared between groups using Fisher exact test or two-sampled t-tests, when indicated. Survival analysis was completed using Kaplan-Meier methodology. A significance level of P < .05 was assumed for all tests.
RESULTS
Preoperative characteristics of the patients. From 2002 to 2015, 27 patients underwent TEVAR with AAC stents. The majority were male (70%; n ¼ 19), with mean age of 69 6 12 years (range, 40-90), and 41% (n ¼ 11) had prior history of either endovascular or open aortic repair. Most had a history of hypertension (96%), coronary disease (59%), and dyslipidemia (56%). Additional details of demographics and comorbidities of the patients are presented in Table I . A majority (67%; n ¼ 18) were treated electively; seven (26%) were urgent-symptomatic, and two (7%) had a diagnosis of rupture (Table II) . Virtually all patients were deemed medically high risk as determined by an American Society of Anesthesiologists classification of 4 (96%; n ¼ 26). The most frequent presenting diagnosis was degenerative thoracic aortic aneurysm (48%).
AAC vessel data and operative characteristics. In total, 32 AAC stents were implanted including the LSA (n ¼ 1), LCCA (n ¼ 24), and innominate artery (n ¼ 6), and one additional chimney was placed into a pre-existing ascending aortic arch innominate/carotid debranching graft. A single chimney was used in 22 patients (83%), and 75% (n ¼ 24) of chimney placements occurred electively. Additional details of Ishimaru 18 zone deployment, chimney target vessel, and implant strategy are highlighted in Fig 3 and Table III . Twenty patients (74%) had either pre-emptive or concomitant left carotid-subclavian bypass. Excluding the unplanned LSA chimney, the remaining six patients in the series did not undergo subclavian revascularization. These cases occurred early in the experience and before guidelines 22 became available regarding LSA revascularization during TEVAR. Multiple combinations of TEVAR graft and AAC stent combinations were used (Supplementary Table I , online only).
The most common TEVAR device used was a Zenith TX2 (70%; n ¼ 19), and the most common brachiocephalic chimney devices were a self-expanding covered stent graft (Gore Viabahn) and balloon-expandable covered stent graft (Atrium iCAST; n ¼ 26 of 32; 81%). Internal reinforcement with a balloon or self-expandable stent (Zilver 518) was employed in 31% (n ¼ 10) of AAC stents. Specific information on intraoperative adjunct, procedural details, and chimney stent types are listed in Table IV .
Postoperative outcomes and complications. Mean length of stay was 9 6 9 days (median, 5.5; range, 1-36). Of surviving patients, the majority (65%; n ¼ 17) were discharged to either home or short-term rehabilitation, whereas four patients (15%) were transferred to a long-term acute care facility. The 30-day and overall in-hospital mortality rate was 4% (n ¼ 1). A description of the major postoperative neurologic, cardiopulmonary, and renal complications is listed in Table V . Seven patients (26%; n ¼ 4, elective; n ¼ 2, urgent-symptomatic; n ¼ 1, emergent-ruptured) had a major postoperative complication, with four patients suffering multiple complications. No episodes of spinal cord ischemia occurred. However, three patients (11%) suffered a postoperative stroke, two of which had complete clinical resolution, with one having a persistent severe neurologic deficit at discharge (major stroke rate: 4%). Notably, all three patients experiencing a stroke were in cases of unplanned AAC deployment. Details of these three cases are further outlined in Supplementary Table II  (online only) .
Follow-up, endoleak, and reintervention. The median clinical follow-up time was 9 (range, 1-23) months. At least one postoperative CTA study was available for 24 of 26 surviving patients. No stent migration, component separations, fractures, retrograde dissections, or aneurysm ruptures occurred during follow-up. Nine (33%) patients underwent aorta-related reintervention, and no ACC occlusion events were identified during the study interval. Three patients underwent open conversion during follow-up (type Ia endoleak, n ¼ 1; false lumen aneurysm expansion/persistent perfusion, n ¼ 2). Estimated freedom from any aorta-related or non-aortarelated reintervention at 12 months was 48% 6 13% (Fig 4) . Additional detailed descriptions of perioperative events as well as timing and nature of reinterventions are highlighted in Table VI .
Notably, the rate of any type of intraoperative endoleak was 11% (n ¼ 3; type Ia, n ¼ 2). The two patients experiencing intraoperative type Ia endoleak did not undergo subsequent remediation in follow-up as their aortic diameters decreased and the endoleaks resolved. There were four additional patients who developed an endoleak during follow-up. Only one of these patients was noted to have a type Ia endoleak at 12 months postoperatively; however, this did lead to open conversion with arch reconstruction.
AAC-related reinterventions occurred in three patients. One case was due to coronary-subclavian steal from LCCA chimney compression requiring chimney extension 2 months postoperatively. The second AAC-related reintervention occurred 1 month postoperatively and was also for significant LCCA chimney compression that was remediated using a self-expanding stent. The final patient underwent proximal TEVAR extension requiring extension of a carotid chimney 3 months after the index procedure. The AAC primary patency is estimated to be 89% 6 6% at 12 months (Fig 5) .
Fourteen patients have $6 months of clinical follow-up time with appropriate imaging follow-up. In these patients, diameter stabilization was detected in 11 (79%), whereas significant reduction ($5 mm) occurred in 7 (50%). Overall, mean survival time was 62 (standard error, 6 6; 95% confidence interval for mean, 50-74) months. The 1-year and 3-year survival is estimated to be 88% 6 6% and 69% 6 9%, respectively (Fig 6) . There were five late deaths; however, all were due to nonaorta-related disease (pneumonia resulting in respiratory failure, two; myocardial infarction, three, none related to supra-aortic trunk vessel patency/left internal mammary graft compromise).
DISCUSSION
This study represents the largest published experience of AAC stents with TEVAR for zone 0 and zone 1 deployments; it further supports the role of these procedures for the treatment of high-risk patients with complex proximal thoracic and transverse aortic arch disease and as a salvage maneuver for unintentional branch coverage. These data demonstrate that good short-term results can be achieved relative to previously reported outcomes after direct arch reconstruction or debranching. Notably, despite a cohort with a high medical and anatomic risk, excellent technical success with relatively low morbidity and mortality was observed, especially in patients with planned AAC procedures. No AAC occlusion events occurred, but three reinterventions were required for significant proximal stenosis related to stent compression. The overall reintervention rate was significant and also reflected the need for future treatment of synchronous or metachronous aortic disease.
The historical "gold standard" for repair of proximal descending and transverse aortic arch disease is open surgical repair, but outcomes of mixed hemiarch and total arch repair with elephant trunk or frozen elephant trunk have variable elective morbidity (15%-40%) and mortality rates (6%-22%). [25] [26] [27] Because of mixed pathologic processes, presentations, and complexity of these procedures, it is difficult to characterize which factors drive outcomes in these series. [28] [29] [30] With improvements in operative technique and perioperative care, contemporary results show that 30-day mortality for patients undergoing open thoracic aortic repair ranges between 2% and 20%. 28, 29 In the absence of aortic dissection, centers of excellence frequently report elective mortality rates <5% for good-risk patients. However, there are subsets of patients with proximal thoracic and transverse aortic arch disease with significant comorbidities who may be deemed poor candidates for conventional open repair. 31 The morbidity of open thoracic aortic repair, especially in poor-risk candidates, is sobering, with 30-day morbidity and mortality rates of 30% to 50% and 10% to 20%, respectively.
28
This series represents a high-risk population as evidenced by preoperative American Society of Anesthesiologists scores, comorbidities, and presentation and the history of previous aortic repair in 41%. Importantly, all were thought to be at prohibitively high risk for open repair by a group of experienced vascular and cardiothoracic surgeons at a tertiary care medical center with a practice that collectively treats approximately 600 aortic patients per year. Notably, nine of our patients in this series presented nonelectively, and despite that presentation, eight of these nine (89%) not only survived repair but were discharged to home or a short-term rehabilitation facility. Several reports highlight that TEVAR with AAC is associated with lower mortality risk 17, 32 32 Other authors have advocated laser in situ aortic graft fenestration for LSA revascularization, which may provide an additional treatment choice in a subset of patients, especially once this method can be extended to more proximal vessels. 37 However, the impact of laser fenestration on device integrity and durability is unknown.
The results of this analysis compare favorably with a meta-analysis of 124 TEVAR patients and 136 AAC grafts by Moulakakis et al, 10 who demonstrated a perioperative mortality and stroke rate of 5% and 4%, respectively. Our series had a single perioperative mortality event (4%) in a patient with a ruptured arch aneurysm, with a stroke rate of 11%. Whereas definitive conclusions about the stroke risk are difficult to make, given the heterogeneity of the patients' presentations, it is notable that all of the strokes occurred in unplanned AAC cases. Aortoiliac tortuosity and arch angulation were thought to be significant contributing factors in each of these cases that led to inadvertent supra-aortic trunk vessel coverage. Presumably, the strokes may have been related to temporary coverage of vessel ostia, along with the additional arch manipulation that is required to perform an unplanned AAC. This Kaplan-Meier curve with 95% confidence intervals demonstrates the estimated freedom from any aorta-related or non-aorta-related reintervention. The 12-month estimated freedom from reintervention is 48% 6 13% (standard error of the mean [SEM] exceeds 10% at 11 months). Because of the complexity of the pathologic process that was selected for these procedures, patients underwent various types of reintervention, including remote aortic site operations for synchronous or metachronous disease as well as remediation of the index aortic repair.
Like others, 38 despite the high technical success and acceptable short-term outcomes, we remain concerned about the durability of AAC because of endoleak and arch vessel patency. Concerns about "gutter leaks" were initially raised by Sugiura et al 39 when they reported midterm outcomes after 11 AAC procedures and 2 (18%) patients developed type Ia endoleak. Furthermore, the pooled endoleak rate estimates from multiple series were 19%, with 11% due to type Ia endoleak. 10, 32 Indeed, three patients (11%) in our experience were noted to have type Ia endoleak within the first postoperative year, with one resulting in open conversion (Table VI) . Importantly, the other two patients had resolution of their endoleak within the initial postoperative year and continued to have stable aortic diameters during follow-up. The reintervention rate in this study (33%) exceeds that of other AAC series, in which estimates of 10% to 25% have been reported. 10 We think that several important differences are likely to explain the higher reintervention rate in our series. Specifically, 84% of cases in the reported literature had a single chimney, with >50% of those in the LSA, which is much different from our series.
With the exception of a single procedure, all cases in this experience used either zone 0 or zone 1 with an LCCA stent and left carotid-subclavian bypass, and 19% (n ¼ 5) of cases employed a "double-barrel" 16 chimney
technique. In addition, our series includes six different aortic pathologic processes, with >30% of them being nonelective. Furthermore, many (n ¼ 4) of the aortarelated reinterventions occurred outside of the initial intended treatment zone. The technical conduct of AAC implantation during TEVAR has several important considerations regarding device choice and aortic landing zones. We concur with Gehringhoff et al, 17 who reported a preference for covered stents, given the potential for erosion of the main aortic graft with bare-metal stents and the decreased likelihood for endoleak. In this series, we used a variety of thoracic/branch stent graft devices; therefore, it was not possible for us to perform intragraft comparisons or to provide specific recommendations about device combinations. We generally plan to achieve at least 2 to 3 cm of seal in normal-diameter aorta in most cases, especially in cases of degenerative aneurysm. This is consistent with our philosophy for endovascular treatment of visceral aortic disease. 21, 40 In general, we oversize chimney stents by 10% to 20% and oversize the thoracic endograft by approximately 30%, except in acute dissection, in which oversizing is typically minimized to 0% to 10%. Finally, our threshold for internal AAC stent reinforcement is low because the device-to-device and device-to-vessel interaction may
The primary patency of brachiocephalic chimney stents is estimated to be 89% 6 6% at 1 year. Three patients underwent chimney-related reintervention during followup; however, no occlusion events occurred. Reintervention occurred for either stent compression (>50% stenosis) on follow-up computed tomography imaging or proximal extension of the chimney to facilitate more proximal thoracic endovascular aortic repair (TEVAR). All displayed intervals have <10% standard error of the mean. The image also depicts the 95% confidence interval.
Fig 6.
Survival after thoracic endovascular aortic repair (TEVAR) with brachiocephalic chimney stents is estimated to be 88% 6 6% and 69% 6 9% at 1 year and 3 years, respectively, in this high-risk population. All displayed intervals have <10% standard error of the mean. The image also depicts the 95% confidence interval.
lead to extrinsic compression, as was seen in two of our patients who underwent reintervention.
Limitations. This study has several inherent limitations related to its retrospective single-center design with heterogeneous groups of patients. There is certainly an inherent selection bias based on multiple physiologic, anatomic, and comorbid factors. Although this is one of the largest AAC series reported to date, the sample size is small. The chimney techniques evolved with experience and with changes in device availability, so it is difficult to identify a homogeneous strategy that affords more predictable outcomes. Importantly, our overall follow-up was short, and the reintervention rates certainly raise concerns about long-term durability. This issue is particularly important in a population of patients that has advanced comorbidity with complex multilevel aortic disease. Despite our center's extensive experience with complex aortic disease, long-term imaging follow-up has been challenging to obtain in this cohort of complex patients referred from a large geographic region. This limitation has been recently addressed by improved coordination of image data sharing from referring providers through cloud-based services.
CONCLUSIONS
The AAC technique used during TEVAR can be performed safely with a high rate of technical success, with acceptable perioperative morbidity and mortality rates, even in high-risk patients. Whereas the technique is highly applicable to elective and nonelective presentations, neurologic morbidity remains a concern, especially when AAC placement is unplanned. Importantly, reintervention is not uncommon; thus, close postoperative follow-up is crucial, and anticipated compliance of the patient should be part of the clinical decision-making before these procedures are offered. Larger series with longer follow-up are needed to further define optimal selection of patients and devices and to understand the implications of reintervention. 
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